Aardvark Therapeutics initiated with an Outperform at RBC Capital
RBC Capital analyst Brian Abrahams initiated coverage of Aardvark Therapeutics (AARD) with an Outperform rating and $21 price target Aardvark ...
Aardvark Therapeutics initiated with an Overweight at Morgan Stanley
Morgan Stanley initiated coverage of Aardvark Therapeutics (AARD) with an Overweight rating and $29 price target The firm believes the Phase 2 ...